# Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

> **NCT04990921** · PHASE2 · RECRUITING · sponsor: **University of Louisville** · enrollment: 15 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** Palliative Radiation and Pembrolizumab

## Key facts

- **NCT ID:** NCT04990921
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-02
- **Primary completion:** 2031-07-01
- **Final completion:** 2031-07-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04990921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04990921, "Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04990921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*